| Autor: |
Eisenberg, Mark, Areesha Moiz |
| Rok vydání: |
2023 |
| Předmět: |
|
| DOI: |
10.17605/osf.io/6g7j4 |
| Popis: |
Overweight and obesity are significant public health challenges that reduce life expectancy and are associated with important morbidity and decreased quality of life. While lifestyle interventions have been the mainstay for the management of overweight and obesity, advances in pharmacological therapy have expanded treatment options for individuals with overweight or obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication which have been used for glycemic control among patients with type 2 diabetes. Trials conducted in this population have demonstrated that their use is associated with clinically important weight loss. However, their effects on body weight among individuals without diabetes remains unclear. Several recent randomized controlled trials (RCTs) have been conducted which examined the use of semaglutide for weight loss in adults with overweight or obesity. We will conduct a systematic review and meta-analysis of RCTs to examine the efficacy of once-weekly semaglutide use for weight loss among patients without diabetes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
